Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment. Patients received daratumumab 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood
मुख्य लेखकों: Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2017
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570682/
https://ncbi.nlm.nih.gov/pubmed/28637662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-785246
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन